Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication

Aug 09 2021

• By Alaric DeArment

Doctor with Mammography - Image — AstraZeneca and Daiichi Sankyo announced positive topline results for Enhertu in second-line breast cancer • Source: Shutterstock

Related Content

AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer

May 10 2021

Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market

Jun 09 2021

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Aug 09 2021

AstraZeneca’s Soriot Dismisses Any Pfizer Vaccine ‘Envy’ Amid Buoyant Q2 Results

Jul 29 2021

Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch

Apr 18 2020

DESTINY Calls For Daiichi Sankyo/AZ’s Enhertu In Other Indications

Jun 01 2020

Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

Mar 29 2019

Related Companies

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Roche Holding AG

RemeGen Ltd.

Byondis B.V.

Additional Topics

Clinical Trials Research & Development Business Strategies Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.